AccurKardia delivers automated clinical-grade ECG interpretation software to cardiac monitoring companies, thereby expanding access to the benefits of remote cardiac care to millions of patients worldwide. AccurKardia combines proprietary AI and non-AI based techniques to provide near-real time ECG analytics in the cloud, on device, and at the edge. The Company is part of Cohort 3 of Mayo Clinic Platform_Accelerate and first 510(k) filing is under review by FDA.
Location: United States, New York
Employees: 11-50
Total raised: $3.2M
Founded date: 2019
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.06.2023 | Seed | $2.7M | - |
| 12.07.2021 | Pre-Seed | $500K | - |
Mentions in press and media 3
| Date | Title | Description |
| 22.06.2023 | Medical AI: AccurKardia Secures $2.7M for Clinical Grade ECG Analytics | What You Should Know: AccurKardia, Inc., a New York-based medical AI software company delivering clinical-grade ECG interpretation software to cardiac monitoring companies raises $2.7M in seed funding led by Popular Impact Fund alongside ot... |
| 21.06.2023 | AccurKardia Closes $2.7M Seed Funding | AccurKadia, a New York-based medical AI software company, raised $2.7M in Seed funding. The round saw participation from Popular Impact Fund alongside other private investors. The company intends to use the funds to expand operations and R&... |
| - | AccurKardia | “AccurKardia” |